Previous close | 14.50 |
Open | 14.50 |
Bid | 10.40 |
Ask | 13.50 |
Strike | 165.00 |
Expiry date | 2026-01-16 |
Day's range | 14.50 - 14.50 |
Contract range | N/A |
Volume | |
Open interest | 15 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.